Our team is developing an innovative targeted cancer therapy against methylation modifications on the tyrosine kinase epidermal growth factor receptor (EGFR). Methylation of two arginine residues in the extracellular domain of EGFR enhances ligand binding and oncogenic signaling. We have developed antibody-drug conjugates (ADCs) that specifically target methylated EGFR, aiming to establish a first-in-class therapeutic strategy for triple-negative breast cancer and other solid tumors.

The RAMeE platform is a breakthrough that identifies methylated EGFR (meEGFR) in the extracellular domain as a cancer-specific antigen driving tumor growth and therapy resistance. It enabled the creation of first antibody series targeting meEGFR, surpassing conventional antibodies only recognizing unmodified proteins. By targeting epigenetic changes on membrane receptors, it improves tumor specificity and therapy precision. RAMeE offers new biomarker discovery and a path to targeted therapy.

The RAMeE platform specifically recognizes methylated EGFR (meEGFR), a novel key antigen with tumor-promoting function. Analysis of clinical tumor samples suggests its strong prognostic and predictive value. We are actively developing antibody-drug conjugates (ADCs) and CAR-NK cell therapies targeting meEGFR. This technology shows great promise for commercialization and offers a feasible path toward first-in-class drug development and precision oncology applications targeting difficult cancers.